|1.||Simard, J Marc: 26 articles (01/2016 - 04/2006)|
|2.||Gerzanich, Volodymyr: 19 articles (11/2015 - 04/2006)|
|3.||Rahmatullah, Mohammed: 11 articles (11/2015 - 01/2011)|
|4.||Pari, L: 10 articles (03/2005 - 11/2002)|
|5.||Ivanova, Svetlana: 9 articles (11/2015 - 04/2006)|
|6.||Koren, Gideon: 8 articles (03/2015 - 01/2003)|
|7.||Rahman, Shahnaz: 8 articles (01/2014 - 01/2011)|
|8.||Hebert, Mary F: 7 articles (12/2014 - 12/2007)|
|9.||Kimberly, W Taylor: 6 articles (01/2016 - 09/2012)|
|10.||Sheth, Kevin N: 6 articles (01/2016 - 09/2012)|
|1.||Type 2 Diabetes Mellitus (MODY)
01/01/2002 - "Compared with glyburide, Mix75/25 significantly improved glycemic control in older patients with type 2 diabetes mellitus, could be administered after meals without compromising glycemic control, and was well tolerated."
01/01/1984 - "Glyburide is an improved drug for the management of non-insulin-dependent diabetes mellitus (NIDDM). "
08/01/2011 - "The type 2 diabetes mellitus patients participating in this study with variant genotypes of CYP2C9 were found to respond better to treatment with glibenclamide than those with the normal genotype. "
08/01/2011 - "The aim of this study was to investigate the influence of genetic polymorphisms of CYP2C9 on the response to glibenclamide and on glibenclamide plasma levels in type 2 diabetes mellitus patients. "
03/01/1998 - "In this study nine patients with Type 2 diabetes mellitus were subjected to four treatments in random order on separate days: (A) endurance exercise after the administration of 3.5 mg glibenclamide; (B) as A but given only 1.75 mg glibenclamide; (C) as A but with placebo; (D) rest and administration of 1.75 mg glibenclamide. "
|2.||Gestational Diabetes (Gestational Diabetes Mellitus)
05/01/2001 - "A recent human study has shown glyburide to minimally cross the placenta, allowing a safe new treatment for gestational diabetes. "
03/01/2008 - "To date, there has been only one randomized controlled trial investigating the use of glyburide which found it to be safe and effective in the management of gestational diabetes mellitus. "
02/01/2008 - "Glyburide is a safe and effective treatment for gestational diabetes."
01/01/2015 - "Use of glyburide to treat gestational diabetes is linked to adverse outcomes in babies, study finds."
06/01/2010 - "Initial studies regarding glyburide for treatment of gestational diabetes are promising. "
01/01/1999 - "From this study it seems that there is a marked decrease in CBF but this did not result in impaired myocardial function after a period of ischemia, so it appears that there are no startling side effects of glibenclamide in the ischemic rat heart."
12/01/1993 - "At concentrations of 3, 10 and 30 microM of glibenclamide, a K channel blocker, a significant reduction in the incidence of reperfusion-induced VF and VT was observed, and an attenuation in the maldistribution of myocardial ion contents induced by ischemia/reperfusion was found. "
12/01/2005 - "In Study 2, recovery of function in intermittent cross-clamp fibrillation hearts (62+/-3%) was significantly (p<0.05) higher than intermittent cross-clamp fibrillation hearts treated with glibenclamide (33+/-2%) and ischemia hearts (30+/-5%). "
01/01/2015 - "Some groups received glibenclamide (KATP channel inhibitor; 5mg/kg) before ischemia (45min) and reperfusion (24h). "
12/01/2011 - "Cardiac conduction time was prolonged by low-flow ischemia in isolated, perfused mouse hearts, which was prevented by glibenclamide. "
|4.||Body Weight (Weight, Body)
10/01/2010 - "The efficacy of the root extract was found to be equivalent when compared to the standard hypoglycemic drug glibenclamide (1.25 mg/kg body weight/day, orally) in diabetic rats."
09/01/2014 - "RME and glibenclamide treated rats were maintained the body weight during the study period while as the body weight of diabetic rats had gone down. "
01/01/2013 - "The extract and glibenclamide not only prevented a further body weight loss but also maintained the body weight during the study period. "
12/01/2015 - "Group C and D received 1.0mL 500mg/kg body weight free and bound polyphenol extracts respectively while group E received 1.0mL 0.6mg/kg of glibenclamide. "
12/01/2014 - "speciosus (CSREt) in doses of 200, 400, and 600 mg/kg body weight, and 600 µg/kg body weight of the standard drug glibenclamide for 4 weeks. "
01/01/2016 - "Blockade of this channel by the small molecule glyburide results in improved survival and neurological outcome in multiple preclinical models of ischemic stroke. "
04/01/2014 - "The findings reviewed here provide a strong foundation for a translational research program to study glibenclamide in patients with ischemic stroke."
01/01/2016 - "A robust, compelling body of evidence suggests that an intravenous formulation of glyburide, RP-1127, can prevent swelling and improve outcome in patients with stroke. "
01/01/2016 - "Human Data Supporting Glyburide in Ischemic Stroke."
01/01/2015 - "Glibenclamide for the treatment of ischemic and hemorrhagic stroke."
|4.||Blood Glucose (Blood Sugar)
|5.||Adenosine Triphosphate (ATP)
|2.||Chinese Traditional Medicine (Traditional Chinese Medicine)